高血压患者体内的基质金属蛋白酶-2、-9及金属蛋白酶组织抑制剂-1

Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.

作者信息

Derosa Giuseppe, D'Angelo Angela, Ciccarelli Leonardina, Piccinni Mario N, Pricolo Fabio, Salvadeo Sibilla, Montagna Lorenza, Gravina Alessia, Ferrari Ilaria, Galli Simona, Paniga Sonia, Tinelli Carmine, Cicero Arrigo F G

机构信息

Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.

出版信息

Endothelium. 2006 May-Jun;13(3):227-31. doi: 10.1080/10623320600780942.

DOI:10.1080/10623320600780942

PMID:16840178

Abstract

There are conflicting data in the literature regarding the expression pattern of the vascular matrix metalloproteinase (MMP) system and their inhibitors (TIMPs) in human hypertension. The authors hypothesized that MMP-2, MMP-9, and TIMP-1 would be abnormal in hypertension, reflecting alterations in extracellular matrix (ECM) turnover. The authors measured plasma levels and activities of MMP-2, MMP-9, and TIMP-1 in 44 hypertensive patients and 44 controls. MMP-2 levels and activity were significantly higher in hypertensive group (p < .0001). Significant increase was also observed for MMP-9 level and activity (p < .0001) and for TIMP-1 (p < .0001) in hypertensive patients. Plasma levels and activities of MMP-2, MMP-9, and TIMP-1 are increased in hypertensive patients, which may reflect abnormal ECM metabolism.

摘要

关于血管基质金属蛋白酶（MMP）系统及其抑制剂（TIMP）在人类高血压中的表达模式，文献中的数据存在冲突。作者推测，MMP - 2、MMP - 9和TIMP - 1在高血压中会出现异常，这反映了细胞外基质（ECM）周转的改变。作者测量了44例高血压患者和44例对照者血浆中MMP - 2、MMP - 9和TIMP - 1的水平及活性。高血压组中MMP - 2的水平和活性显著更高（p < .0001）。高血压患者的MMP - 9水平和活性（p < .0001）以及TIMP - 1（p < .0001）也观察到显著升高。高血压患者血浆中MMP - 2、MMP - 9和TIMP - 1的水平及活性升高，这可能反映了ECM代谢异常。